Epizyme, Inc.
EZH2 INHIBITORS FOR TREATING CANCER

Last updated:

Abstract:

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

Status:
Application
Type:

Utility

Filling date:

14 Sep 2021

Issue date:

7 Apr 2022